C - Chemistry – Metallurgy – 07 – D
Patent
C - Chemistry, Metallurgy
07
D
C07D 417/04 (2006.01) A61K 31/381 (2006.01) A61K 31/415 (2006.01) A61K 31/4168 (2006.01) A61K 31/4196 (2006.01) A61K 31/426 (2006.01) A61K 31/427 (2006.01) A61K 31/433 (2006.01) A61K 31/4439 (2006.01) A61K 31/5377 (2006.01) A61P 7/02 (2006.01) A61P 43/00 (2006.01) C07D 213/73 (2006.01) C07D 231/40 (2006.01) C07D 231/52 (2006.01) C07D 233/88 (2006.01) C07D 239/14 (2006.01) C07D 249/14 (2006.01) C07D 277/46 (2006.01) C07D 277/60 (2006.01) C07D 277/82 (2006.01) C07D 285/08 (2006.01) C07D 285/12 (2006.01) C07D
Patent
CA 2397018
Pharmaceutical compositions containing as an active ingredient compounds of the general formula (I), prodrugs of the same, pharmaceutically acceptable salts of both, or solvates of them and exhibiting thrombopoietin receptor agonism: X1-Y1-Z1-W1 (I) wherein X1 is optionally substituted aryl, optionally substituted heteroaryl or the like; Y1 is -NR A CO-(CH2)0-2- or the like (wherein R A is a hydrogen or the like); Z1 is optionally substituted phenylene or the like; and W1 is a group represeted by the below formula: (see formula II) wherein R1, R2, R3, and R4 are each independently a hydrogen atom, optionally substituted lower alkyl or the like, a broken line (---) represents the presence or absence of bond.
L'invention concerne des compositions pharmaceutiques présentant un agonisme vis à vis de la thrombopoïétine, lesquelles contiennent en tant que composés ingrédients actifs de la formule générale (I): X?1¿-Y?1¿-Z?1¿-W?1¿ des promédicaments de celle-ci, des sels pharmaceutiquement acceptables des deux ou leurs solvates, formule dans laquelle X?1¿ représente aryle facultativement substitué, hétéroaryle facultativement substitué ou analogue; Y?1¿ représente -NR?A¿CO-(CH¿2?)¿0-2?- (où R?A¿ représente hydrogène ou analogue) ou analogue; Z?1¿ représente phénylène facultativement substitué ou analogue; et W?1¿ représente un groupe de la formule générale (II) (dans laquelle R?1¿, R?2¿, R?3¿ et R?4¿ représentent chacun indépendamment hydrogène, alkyle inférieur facultativement substitué ou analogue; et la ligne discontinue représente la présence ou l'absence d'une liaison), ou analogue.
Shiota Takeshi
Takayama Masami
Takemoto Hiroshi
Mccarthy Tetrault Llp
Shionogi & Co. Ltd.
LandOfFree
Compounds exhibiting thrombopoietin receptor agonism does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compounds exhibiting thrombopoietin receptor agonism, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds exhibiting thrombopoietin receptor agonism will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1658337